报价延迟最少15分钟:2026/01/07 17:05 EST
盘后时段
|
||||
|
3.95 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
4
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.92/-0.90
|
|
企业价值
423.08M
|
| 资产负债 |
|
每股账面净值
0.70
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.56M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
